House Bill 1393, which aims to give parents of children with IEPs more of a choice in their child’s education, is headed to the Senate for further consideration.

Investing.com -- Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell 1.5% following a U.S. appeals court decision that upheld a previous ruling, effectively denying a stay on ...

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...

Kylie Jenner has come under fire for allegedly treating Timothee Chalamet like a 'possession', with their relationship likened to that of a mother and son rather than a romantic couple, following ...

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron Pharmaceuticals Inc. ‘s Eylea blockbuster eye-disease biologic.

This arrangement, the lawsuit claims, effectively lowered Eylea's selling price and provided Regeneron with a competitive advantage in the anti-VEGF medication market. The Department of Justice ...

A bill to raise the age of consent is working its way through the Oklahoma legislature, and local child advocates expressed on Wednesday that it is a step in the right direction. Senate Bill 445 ...

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CEST The issuer is solely responsible for ...